Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.43 USD
-0.09 (-3.57%)
Updated May 28, 2024 04:00 PM ET
After-Market: $2.42 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Company Summary
South San Francisco, CA-based Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company primarily focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer treatment.
The company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — ALLO-501, cemacabtagene ansegedleucel (cema-cel, or formerly ALLO-501A), ALLO-605, ALLO-316 and ALLO-715 — and a monoclonal antibody (mAB), ALLO-647.
In January 2024, Allogene announced that it is deprioritizing two pivotal mid-stage studies, namely ALPHA2 and EXPAND, evaluating cema-cel in third-line large B cell lymphoma (LBCL). ...
Company Summary
South San Francisco, CA-based Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company primarily focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer treatment.
The company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — ALLO-501, cemacabtagene ansegedleucel (cema-cel, or formerly ALLO-501A), ALLO-605, ALLO-316 and ALLO-715 — and a monoclonal antibody (mAB), ALLO-647.
In January 2024, Allogene announced that it is deprioritizing two pivotal mid-stage studies, namely ALPHA2 and EXPAND, evaluating cema-cel in third-line large B cell lymphoma (LBCL). Management intends to focus on developing cema-cel as a frontline treatment for LBCL patients. In this regard, Allogene has initiated start-up activities for the phase II ALPHA3 study to evaluate cema-cel in first-line LBCL patients.
ALLO-715 and ALLO-605 are being evaluated in the phase I UNIVERSAL study and phase I IGNITE study, respectively, for the same indication — r/r multiple myeloma (MM). ALLO-605 is also the company’s first anti-BCMA TurboCAR T cell therapy. ALLO-316 is being evaluated in a phase I TRAVERSE study for advanced or metastatic clear cell renal cell carcinoma (ccRCC). The mAB candidate, ALLO-647, is part of the lymphodepletion regimen, which is likely to increase the potency of allogeneic CAR T cell therapies.
The company has licensing agreements with companies, including Pfizer, for gaining rights to several technologies or candidates. The company also has a joint venture with Overland Pharma.
With no marketed products in its portfolio, Allogene only generates collaboration revenues. The company generated $0.1 million in 2023, down 39% year over year.
General Information
Allogene Therapeutics, Inc
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-457-2700
Fax: NA
Email: ir@allogene.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 8/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.36 |
Current Year EPS Consensus Estimate | -1.56 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 8/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 2.52 |
52 Week High | 6.05 |
52 Week Low | 2.23 |
Beta | 0.90 |
20 Day Moving Average | 2,384,033.75 |
Target Price Consensus | 13.43 |
4 Week | -11.27 |
12 Week | -53.85 |
YTD | -21.50 |
4 Week | -14.42 |
12 Week | -55.36 |
YTD | -29.41 |
Shares Outstanding (millions) | 170.85 |
Market Capitalization (millions) | 430.55 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 44.12% |
vs. Previous Quarter | 11.63% |
vs. Previous Year | -57.69% |
vs. Previous Quarter | 4.76% |
Price/Book | 0.93 |
Price/Cash Flow | NA |
Price / Sales | 3,311.92 |
3/31/24 | -50.81 |
12/31/23 | -53.76 |
9/30/23 | -54.01 |
3/31/24 | -40.82 |
12/31/23 | -43.24 |
9/30/23 | -43.63 |
3/31/24 | 12.80 |
12/31/23 | 12.38 |
9/30/23 | 12.58 |
3/31/24 | 12.80 |
12/31/23 | 12.38 |
9/30/23 | 12.58 |
3/31/24 | -212,951.53 |
12/31/23 | -194,088.09 |
9/30/23 | -178,954.28 |
3/31/24 | -223,139.98 |
12/31/23 | -202,366.25 |
9/30/23 | -178,954.28 |
3/31/24 | -224,843.84 |
12/31/23 | -344,489.50 |
9/30/23 | -183,817.72 |
3/31/24 | 2.70 |
12/31/23 | 3.04 |
9/30/23 | 3.48 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
9/30/23 | 0.00 |